Oncology early diagnostics
Clinical-grade telomere & cell-biology biomarkers
For more than a decade, Life Length has been conducting research on the efficacy of telomeres as predictive markers for oncological diseases.
Telomeres and cancer
The earliest footprint of malignant transformation
Telomere dysfunction drives genomic instability and enables malignant progression through reactivation of maintenance mechanisms. Measuring telomere dynamics at the single-cell level provides robust biomarkers for cancer risk and precision oncology.
Certified by:
Oncogenesis
≈90% telomerase activation
As oncogenesis progresses, telomeres shorten and ~90% of tumors switch on telomerase, enabling limitless replication.
More aggressive
Telomere dysfunction
Tumor telomeres are typically shorter. Their dysfunction correlates with genomic instability and greater aggressiveness.
Blood as a window
Leukocyte surrogate
Because telomere length is highly correlated across tissues, leukocyte telomere length is a reliable surrogate for tissues of interest.
Evidence base
>7,000 peer-reviewed studies
Telomere alterations are a key biomarker in oncology, supported by a robust and growing body of literature.
Clinical validation of telomere biomarkers for oncology
Clinical validation of TAVs
Clinical validation of Telomere-Associated Variables (TAVs) as oncology biomarkers across multi-center cohorts.
Population reference ranges
Life Length technology compares each patient to curated cohorts to flag biological aging.
Multi-cancer
Valid for several cases. Covered solid tumors, leukemias, and pediatric cancers, among others.
41 hospitals & +7,000 patients
International collaboration with leading centres for recruitment and validation.
ProsTAV®
Telomeric detection biomarker in early prostate cancer diagnosis
CE-IVD Life Length’s algorithm
A blood test for men with PSA 3–10 ng/mL that combines telomere-associated variables to estimate the probability of clinically significant prostate cancer.
Confocal Q-FISH of human cells showing telomere signals (TAT®).
How LifeLengthTech® helps oncology insights
Decision-ready reports
With Life Length patented CLIA and ISO certified Telomere Analysis Technology (TAT®), we quantify the length of every telomere across millions of cells, delivering full distributions (not just averages) for superior clinical and research resolution.
PneumoTAV®
New telomeric biomarker for early lung cancer detection
Confocal Q-FISH of human cells showing telomere signals (TAT®).
